Cargando…

Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation

Purpose: To determine the incidence and risk factors of bleeding events as well as assess the performance of the PRECISE-DAPT score in elderly patients (≥75 years) who underwent percutaneous coronary intervention (PCI) and one-year dual antiplatelet therapy (DAPT). Methods: A total of 940 patients (...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Yanxia, Xu, Bing, Qian, Xiaodong, Cao, Lu, Cheng, Yujia, Liu, Xinjian, Bai, Song, Han, Zhijun, Wang, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362353/
https://www.ncbi.nlm.nih.gov/pubmed/34393770
http://dx.doi.org/10.3389/fphar.2021.661619
_version_ 1783738145019265024
author Qian, Yanxia
Xu, Bing
Qian, Xiaodong
Cao, Lu
Cheng, Yujia
Liu, Xinjian
Bai, Song
Han, Zhijun
Wang, Junhong
author_facet Qian, Yanxia
Xu, Bing
Qian, Xiaodong
Cao, Lu
Cheng, Yujia
Liu, Xinjian
Bai, Song
Han, Zhijun
Wang, Junhong
author_sort Qian, Yanxia
collection PubMed
description Purpose: To determine the incidence and risk factors of bleeding events as well as assess the performance of the PRECISE-DAPT score in elderly patients (≥75 years) who underwent percutaneous coronary intervention (PCI) and one-year dual antiplatelet therapy (DAPT). Methods: A total of 940 patients (≥75 years) who received PCI and one-year DAPT were retrospectively enrolled into the study. The multivariable logistic regression analysis was conducted to identify risk factors of antiplatelet-related bleeding complications. The receiver operating characteristic (ROC) curve analysis and the Delong test were performed to obtain the optimized PRECISE-DAPT score. Results: It was observed that 89 (9.47%) patients suffered bleeding complications, while 37 (3.94%) of them had the Bleeding Academic Research Consortium (BARC, type ≥2) bleeding events. We stratified the PRECISE-DAPT score in tertiles (T1: ≤23; T2:24 to 32; T3: ≥33) and found that BARC ≥ 2 type bleeding occurred more frequently in T3 than in T1 and T2 (8.25 vs. 1.46% vs. 2.40%, p <0.05). The ROC curve analysis revealed that the PRECISE-DAPT score cutoff for BARC ≥2 type bleeding prediction was 33. In comparison with the current recommended cutoff score of 25 (AUC: 0.608, based on ROC analysis), the Delong test indicated significantly improved ability for predicting BARC ≥ 2 type bleeding events using the proposed cutoff value of 33, AUC of 0.676 (p = 0.03), and Brier Score of 0.04. The multivariable logistic regression analysis demonstrated that the PRECISE-DAPT score ≥ 33 [OR: 3.772; 95% CI (1.229, 11.578); p = 0.02] was associated with BARC ≥ 2 type bleeding event, along with a history of hemorrhagic stroke [OR: 6.806; 95% CI (1.465, 31.613); p = 0.014], peptic ulcer [OR: 3.871; 95% CI (1.378, 10.871); p = 0.01], and/or myocardial infarction [MI, OR: 3.081; 95% CI (1.140, 8.326); p = 0.027]. Conclusion: A higher PRECISE-DAPT score of 33 might be a more reasonable cutoff value for predicting BARC ≥2 type bleeding risk in CAD patients (≥75 years). In addition, the history of hemorrhagic stroke, peptic ulcer, and myocardial infarction were identified as the risk factors of BARC ≥2 type bleeding events.
format Online
Article
Text
id pubmed-8362353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83623532021-08-14 Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation Qian, Yanxia Xu, Bing Qian, Xiaodong Cao, Lu Cheng, Yujia Liu, Xinjian Bai, Song Han, Zhijun Wang, Junhong Front Pharmacol Pharmacology Purpose: To determine the incidence and risk factors of bleeding events as well as assess the performance of the PRECISE-DAPT score in elderly patients (≥75 years) who underwent percutaneous coronary intervention (PCI) and one-year dual antiplatelet therapy (DAPT). Methods: A total of 940 patients (≥75 years) who received PCI and one-year DAPT were retrospectively enrolled into the study. The multivariable logistic regression analysis was conducted to identify risk factors of antiplatelet-related bleeding complications. The receiver operating characteristic (ROC) curve analysis and the Delong test were performed to obtain the optimized PRECISE-DAPT score. Results: It was observed that 89 (9.47%) patients suffered bleeding complications, while 37 (3.94%) of them had the Bleeding Academic Research Consortium (BARC, type ≥2) bleeding events. We stratified the PRECISE-DAPT score in tertiles (T1: ≤23; T2:24 to 32; T3: ≥33) and found that BARC ≥ 2 type bleeding occurred more frequently in T3 than in T1 and T2 (8.25 vs. 1.46% vs. 2.40%, p <0.05). The ROC curve analysis revealed that the PRECISE-DAPT score cutoff for BARC ≥2 type bleeding prediction was 33. In comparison with the current recommended cutoff score of 25 (AUC: 0.608, based on ROC analysis), the Delong test indicated significantly improved ability for predicting BARC ≥ 2 type bleeding events using the proposed cutoff value of 33, AUC of 0.676 (p = 0.03), and Brier Score of 0.04. The multivariable logistic regression analysis demonstrated that the PRECISE-DAPT score ≥ 33 [OR: 3.772; 95% CI (1.229, 11.578); p = 0.02] was associated with BARC ≥ 2 type bleeding event, along with a history of hemorrhagic stroke [OR: 6.806; 95% CI (1.465, 31.613); p = 0.014], peptic ulcer [OR: 3.871; 95% CI (1.378, 10.871); p = 0.01], and/or myocardial infarction [MI, OR: 3.081; 95% CI (1.140, 8.326); p = 0.027]. Conclusion: A higher PRECISE-DAPT score of 33 might be a more reasonable cutoff value for predicting BARC ≥2 type bleeding risk in CAD patients (≥75 years). In addition, the history of hemorrhagic stroke, peptic ulcer, and myocardial infarction were identified as the risk factors of BARC ≥2 type bleeding events. Frontiers Media S.A. 2021-07-30 /pmc/articles/PMC8362353/ /pubmed/34393770 http://dx.doi.org/10.3389/fphar.2021.661619 Text en Copyright © 2021 Qian, Xu, Qian, Cao, Cheng, Liu, Bai, Han and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Qian, Yanxia
Xu, Bing
Qian, Xiaodong
Cao, Lu
Cheng, Yujia
Liu, Xinjian
Bai, Song
Han, Zhijun
Wang, Junhong
Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
title Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
title_full Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
title_fullStr Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
title_full_unstemmed Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
title_short Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
title_sort incidence and risk factors for antiplatelet therapy–related bleeding complications among elderly patients after coronary stenting: a multicenter retrospective observation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362353/
https://www.ncbi.nlm.nih.gov/pubmed/34393770
http://dx.doi.org/10.3389/fphar.2021.661619
work_keys_str_mv AT qianyanxia incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT xubing incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT qianxiaodong incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT caolu incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT chengyujia incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT liuxinjian incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT baisong incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT hanzhijun incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation
AT wangjunhong incidenceandriskfactorsforantiplatelettherapyrelatedbleedingcomplicationsamongelderlypatientsaftercoronarystentingamulticenterretrospectiveobservation